Explore

Rapid Read Rapid Read
Putin Initiates $26 Billion Anti-Aging Vaccine Project Amid Population Concerns

Putin Initiates $26 Billion Anti-Aging Vaccine Project Amid Population Concerns

Russian President Vladimir Putin has launched a $26 billion initiative to develop an anti-aging vaccine, as part of a national health project aimed at addressing Russia's declining population. The project, which involves gene therapy targeting the RAGE receptor linked to aging, is part of Putin's broader efforts to enhance longevity. The initiative has drawn global attention, with Russia planning to produce the anti-aging drug by 2030. The project is reportedly driven by Mikhail Kovalchuk, a close associate of Putin, who envisions extending human lifespan significantly.
Trendline Trendline
Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics
Trendline Trendline
Foundation Medicine to Launch Pharmacogenetic Offering in Partnership with Fulgent Genetics

Foundation Medicine to Launch Pharmacogenetic Offering in Partnership with Fulgent Genetics

Foundation Medicine to Launch Pharmacogenetic Offering in Partnership with Fulgent Genetics
Rapid Read Rapid Read
Castle Biosciences' TissueCypher Test Enhances Risk Management in Barrett's Esophagus

Castle Biosciences' TissueCypher Test Enhances Risk Management in Barrett's Esophagus

Castle Biosciences, Inc. has announced new data from Mayo Clinic researchers demonstrating the effectiveness of the TissueCypher test in improving risk stratification for patients with Barrett's esophagus. Presented at Digestive Disease Week 2026, the findings show that the test can predict a patient's five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma. The study revealed that the test influenced changes in surveillance intervals for over half of the patients, aligning with the test's risk classification. This molecular test provides more accurate risk assessments compared to traditional histopathology, allowing for more personalized patient management.
Rapid Read Rapid Read
Armatus Bio Develops Scalable Potency Assay Platform for Gene Silencing Therapies

Armatus Bio Develops Scalable Potency Assay Platform for Gene Silencing Therapies

Armatus Bio has introduced a scalable potency assay platform to accelerate the development of gene silencing therapies for neuromuscular diseases such as facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease type 1A (CMT1A). The platform, detailed in a publication in Molecular Therapy Advances, addresses the lack of standardized assays for product consistency and regulatory compliance. By engineering human cell lines with a universal AAV receptor and a luciferase-based reporter system, the platform provides quantifiable, dose-dependent readouts and streamlined assay development.
Trendline Trendline
KROMATID Unveils Genomic Integrity Benchmarking at ASGCT 2026, Enhancing Cell Therapy Development

KROMATID Unveils Genomic Integrity Benchmarking at ASGCT 2026, Enhancing Cell Therapy Development

KROMATID Unveils Genomic Integrity Benchmarking at ASGCT 2026, Enhancing Cell Therapy Development
Rapid Read Rapid Read
Wearable Biosensor Shows Promise in Monitoring Kidney and Liver Function

Wearable Biosensor Shows Promise in Monitoring Kidney and Liver Function

Researchers have developed a new microneedle biosensor capable of real-time monitoring of kidney and liver drug clearance in a rat model. The biosensor, created by Sam Emaminejad and colleagues, uses a nanocavity-textured microneedle electrode paired with a bioanalytical framework to translate interstitial fluid measurements into blood-equivalent pharmacokinetic parameters. The biosensor demonstrated its potential for therapeutic drug monitoring by showing concordance with blood levels of the chemotherapy drug irinotecan in healthy rats. It also detected prolonged drug half-life in rats with liver damage and lower drug clearance in rats with adenine-induced kidney injury.
Rapid Read Rapid Read
Advancements in Non-Viral DNA Integration in Human T Cells Highlight Potential for Cancer Therapy

Advancements in Non-Viral DNA Integration in Human T Cells Highlight Potential for Cancer Therapy

Recent research has focused on the non-viral targeted integration of large DNA sequences into primary human T cells without the need for double-stranded DNA breaks. This method, which avoids the use of viral vectors, represents a significant advancement in the field of gene therapy, particularly for cancer treatment. The study highlights the potential of using CRISPR-associated transposases to achieve precise DNA integration, which could enhance the safety and efficacy of T-cell therapies. This approach aims to mitigate the risks associated with traditional viral vector methods, such as insertional mutagenesis and immune responses. The research underscores the potential for developing more effective and safer CAR T-cell therapies, which are engineered to target and destroy cancer cells.
Trendline Trendline
BreezeBio Advances Non-Viral Gene Delivery Technology for Therapeutics

BreezeBio Advances Non-Viral Gene Delivery Technology for Therapeutics

BreezeBio Advances Non-Viral Gene Delivery Technology for Therapeutics
Rapid Read Rapid Read
New Wearable Biosensor Monitors Kidney and Liver Drug Clearance in Real-Time

New Wearable Biosensor Monitors Kidney and Liver Drug Clearance in Real-Time

Researchers have developed a new microneedle biosensor capable of real-time monitoring of liver and kidney drug clearance. This minimally invasive system, tested in a rat model, uses a nanocavity-textured microneedle electrode paired with a bioanalytical framework to translate interstitial fluid measurements into blood-equivalent pharmacokinetic parameters. The biosensor demonstrated its potential for therapeutic drug monitoring by accurately reflecting drug levels in the blood and detecting prolonged drug half-life in rats with liver damage. Additionally, it showed strong correlation with dose-dependent changes in drug levels in healthy rats and indicated improvements in kidney function in rats recovering from induced kidney injury.
Trendline Trendline
Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain
Trendline Trendline
Futurist Ray Kurzweil Predicts Longevity Escape Velocity by 2029

Futurist Ray Kurzweil Predicts Longevity Escape Velocity by 2029

Futurist Ray Kurzweil Predicts Longevity Escape Velocity by 2029